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Asylum seekers and refugees (AS&Rs) experience impaired mental health and
wellbeing, related to stresses in their country of origin, experiences in transit and
reception on arrival, including significant barriers to accessing mainstream services.
Their contact with healthcare is often crisis-driven and mediated through non-
governmental organisations (NGOs).
 
Problem Management Plus (PM+) is a psychosocial intervention recommended by the
World Health Organization to address distress experienced by adults affected by




In a pilot randomised controlled trial, PM+ will be delivered to AS&Rs in contact with
NGOs in Liverpool City Region, UK, by lay therapists who have lived experience of
forced migration. Following systematic review and stakeholder engagement, PM+ has
been adapted to the local context, and lay therapists have been trained in its delivery.
 
We will assess the feasibility of conducting a three-arm RCT of five 90-minute sessions
of PM+, delivered individually or in groups by lay therapists to AS&Rs experiencing
emotional distress and functional impairment, compared with each other and with usual
support offered by local NGOs. Distress and impairment at baseline will be measured
by Hospital Anxiety and Depression Scale (HADS) and WHO Disability Assessment
Schedule (WHO-DAS). We aim to recruit 105 participants, 35 per arm.
 
Primary health outcomes are anxiety and depressive symptoms at 3 months,
measured by HADS. Secondary outcomes include subjective wellbeing, functional
status, progress on identified problems, post-traumatic stress disorder, depressive
disorder and service usage. Longer term impact will be assessed at 6-months post
baseline, on the same parameters.
 
We will assess the feasibility of conducting a full RCT in relation to the following
elements: recruitment and retention of lay therapists and study participants; fidelity of
delivery of PM+; and suitability of the study measures, including any linguistic or
cultural barriers.
Discussion
We will use these findings to specify the parameters for a full randomised controlled
trial to test the effectiveness and cost effectiveness of PM+ in reducing emotional
distress and health inequalities, and improving functional ability and wellbeing,
amongst asylum seekers and refugees.
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Asylum seekers and refugees (AS&Rs) experience impaired mental health and 
wellbeing, related to stresses in their country of origin, experiences in transit and 
reception on arrival, including significant barriers to accessing mainstream 
services. Their contact with healthcare is often crisis-driven and mediated through 
non-governmental organisations (NGOs).  
 
Problem Management Plus (PM+) is a psychosocial intervention recommended by 
the World Health Organization to address distress experienced by adults affected 
by humanitarian crises. We are investigating its application for the first time in a 
high income country.  
 
Methods 
In a pilot randomised controlled trial, PM+ will be delivered to AS&Rs in contact 
with NGOs in Liverpool City Region, UK, by lay therapists who have lived 
experience of forced migration. Following systematic review and stakeholder 
engagement, PM+ has been adapted to the local context, and lay therapists have 
been trained in its delivery.  
 
We will assess the feasibility of conducting a three-arm RCT of five 90-minute 
sessions of PM+, delivered individually or in groups by lay therapists to AS&Rs 
experiencing emotional distress and functional impairment, compared with each 
other and with usual support offered by local NGOs. Distress and impairment at 
baseline will be measured by Hospital Anxiety and Depression Scale (HADS) and 
WHO Disability Assessment Schedule (WHO-DAS). We aim to recruit 105 
participants, 35 per arm. 
 
Primary health outcomes are anxiety and depressive symptoms at 3 months, 
measured by HADS. Secondary outcomes include subjective wellbeing, functional 
status, progress on identified problems, post-traumatic stress disorder, depressive 
disorder and service usage. Longer term impact will be assessed at 6-months post 
baseline, on the same parameters. 
 
We will assess the feasibility of conducting a full RCT in relation to the following 
elements: recruitment and retention of lay therapists and study participants; 
fidelity of delivery of PM+; and suitability of the study measures, including any 
linguistic or cultural barriers. 
Discussion 
We will use these findings to specify the parameters for a full randomised 
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emotional distress and health inequalities, and improving functional ability and 
wellbeing, amongst asylum seekers and refugees. 
 
 
Trial registration:   
ISRCTN15214107 




Asylum seekers, refugees,  mental health, psychosocial intervention, problem 












































































The United Nations Refugee Agency estimates that 71 million people throughout 
the world have been forced to flee their homes as the number of protracted 
conflicts has increased. This has created more than 26 million refugees worldwide, 
of whom an estimated 126,720 live in the UK1. UK Home Office figures indicate 
there were 34,354 asylum applications in the UK (main applicants only) in the year 
ending September 2019. During that year the UK offered asylum, humanitarian 
protection, alternative forms of leave and resettlement, to 19,480 people; there 
were 35,043 cases pending initial decision, of which 57% were more than 6 months 
old2. Many applications are initially refused as a result of a complex system that 
makes it difficult for asylum seekers and refugees (AS&Rs) to provide the evidence 
needed to meet the criteria for gaining asylum.   
 
AS&Rs have higher prevalence of psychological morbidity, including depression, 
anxiety and post-traumatic stress disorder (PTSD), and functional impairment than 
other migrant groups and local majority populations3-5. Mental health problems are 
particularly prevalent amongst war refugees6, with rates of PTSD up to 10 times 
higher than in the general population7,8. Persistence of mental health problems 
after arrival in a host country is related to poor socio-economic conditions, 
acculturation-related stressors, economic uncertainty and ethno-racial 
discrimination5,9. As a result, AS&Rs encounter extensive barriers to accessing 
health care5,10 and have substantial unmet mental health needs11. In the UK, the 
situation is especially problematic for asylum seekers without leave to remain who 
are at risk of destitution yet are required to pay for specialist health care12,13.   
 
Psychosocial interventions for AS&Rs resettled in high-income countries (HICs) may 
provide significant benefits, however there are few studies of good quality14,15. 
Evidence for the applicability of psychological interventions by non-specialists in 
low and middle-income countries (LMICs) has increased significantly16-19. Many 
countries, including the UK, are seeking to improve health care delivery by 
extending the roles of health professionals20, increasing workforce capacity and 
enhancing quality of care21. Innovations developed in LMICs, including task-
sharing22 and the Common Elements Treatment Approach23, have the potential to 
address current challenges for mental health care in HICs24, notably the lack of 
human resources to deliver mental health services to those in need. 
 
Problem Management Plus (PM+), is a manualised brief multi-component 
intervention25, recommended by the World Health Organisation as part of its 
mhGAP guidelines (http://www.who.int/mental_health/mhgap/en/). It is 
specifically developed to be amenable to cultural and linguistic adaptation for the 
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techniques, the intervention is trans-diagnostic by which we mean it applies the 
same intervention strategies across various common mental health problems 
clients may be experiencing. Addressing multiple problems at one time through 
shared emotional mechanisms is efficient, reducing the practical challenge of 
making differential diagnoses and learning multiple treatment manuals for 
different mental health diagnoses26,27. 
Rationale  
PM+ has shown significant benefit in trials in LMICs25,28,29. However, to date there is 
no evidence of feasibility, effectiveness or cost-effectiveness of interventions such 
as PM+ offered by lay therapists to AS&Rs in HICs.  
 
The rationale for undertaking a pilot trial of PM+ for AS&Rs, rather than 
proceeding to a full multi-centre trial, is that there are several areas of 
uncertainty regarding trial viability. These include the feasibility of recruiting and 
retaining AS&Rs as study participants, the fidelity of intervention delivery, and the 
acceptability and utility of proposed study measures30. There may also be 
inequalities in mental health and wellbeing between AS&R groups, depending on 
their age, gender, nationality, education, occupational status, length of stay, 
access to resources and their current legal status in the UK which could inform the 
design of a full trial. As North West England has the largest number of asylum 
seekers in dispersal accommodation in England (9521 in September 2019) it is a 
suitable setting for the pilot trial.  
 
Preparatory work 
The PROSPER Pilot Trial (hereafter referred to as the PROSPER Pilot) builds on a 
preparatory phase aimed at developing the research team’s understanding of 
relevant issues, engaging with stakeholders, adapting the intervention and training 
the facilitators.   
 
We conducted a systematic review (PROSPERO 2018 CRD42018104453) of barriers 
and facilitators to uptake of psychosocial interventions delivered by lay therapists 
to improve mental health and wellbeing of asylum seekers and migrants. We also 
undertook six focus groups with local service providers and potential service users, 
and held two open meetings for stakeholders, to gather views about the mental 
health needs of AS&Rs and the potential utility of PM+.  
 
As a result, we made the following contextual modifications to promote uptake 
and relevance of the PROSPER Pilot:  
 Focus on English, Arabic, Farsi and Urdu, identified as four most common 
languages currently spoken by AS&Rs in Liverpool City Region.  
 Decision to exclude new arrivals and those in temporary accommodation: on 
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intervention and/or follow-up; and b) low probability of being registered with a 
GP and hence unable to access trial safeguarding procedures.   
 Alteration to text of PM+ manuals to reflect life in western urban settings, 
rather than south Asian rural settings: e.g. ‘home’ not ‘hut’, ‘reading’ not 
‘rearing poultry’, ‘visit job centre’ not ‘speak with village elder’. 
 Adapting the group PM+ case studies to include men. 
 Matching therapists and participants on basis of gender and language, but not 
on basis of religion, politics or culture. 
 Identification of accessible ‘safe spaces’ for research interviews and delivery of 
PM+ sessions, including availability of child care. 
 Reimbursement of travel expenses for lay therapists and participants. 
 Supervision and support of lay therapists to include boundary issues between 
therapy and involvement in participants’ lives, since the shared lived-
experience of the asylum process takes this study beyond the boundaries that 
have been apparent in other contexts. 
 
Training 
Person Shaped Support (PSS) is a health and social care charity, responsible for 
training in and delivery of the PROSPER intervention.  PSS provides a wide array of 
services, including Spinning World, a specialist psychological therapies service for 
AS&Rs and others who have experienced human right abuses and traumatic events.    
 
Two wellbeing mentors were appointed by PSS in September 2018. The following 
month they and their supervisor received five days of intensive training from two 
PM+ Master Trainers (from Liverpool and Amsterdam). This focused on the delivery 
of the PM+ intervention strategies in both individual and group modalities, and on 
skills in training and supervising lay therapists. Subsequently the wellbeing mentors 
completed practice cases to embed their skills, and receive regular monthly 
supervision from one of the PM+ Master Trainers which will continue throughout 
the study. 
 
Fifteen people with lived experience of the asylum process were offered training 
lay therapists, after a recruitment procedure organised through PSS. Training 
began in March 2019 and included education in mental disorders, basic helping 
skills, delivery of intervention strategies and self-care.  Lay therapists received a 
total of eight days of training, and were trained to deliver either individual or 
group PM+. This was followed by training cases and a competency assessment. Ten 
lay therapists successfully completed training and were assessed as competent: six 
in individual PM+ (two Farsi-speaking men, one Arabic-speaking man, and three 
women whose languages are Urdu, Farsi and English) and four in group PM+ (one 








































































Page 8 of 31 
Methods 
Aim and objectives  
This pilot trial is part of the PROSPER feasibility study, the overall aim of which is 
to determine whether it is possible to conduct a randomised controlled trial in the 
UK of the evidence-based PM+ psychosocial intervention, delivered by lay 
therapists for distressed and functionally impaired asylum seekers and refugees. 
The primary objective of the PROSPER Pilot is to provide preliminary information 
on the potential effectiveness of group or individual PM+ versus standard care for 
AS&Rs, assessed using severity of combined anxiety and depressive symptoms at 13 
weeks post-baseline measured using the Hospital Anxiety and Depression Scale 
(HADS). 
The secondary objectives are to provide preliminary information on the potential 
effectiveness and cost-effectiveness of group or individual PM+ versus standard 
care for AS&Rs with regards to: 
o Severity of combined anxiety and depressive symptoms at 26 weeks; 
o Subjective wellbeing;  
o Functional impairment; 
o Progress on problems for which an individual has sought help; 
o Post-traumatic stress disorder; 
o Depressive disorder; and 
o Use of services and supports from NHS, social care and voluntary 
organisations. 
Design and setting 
PROSPER Pilot is designed as a three-arm pilot study, with the features of a 
proposed future definitive randomised controlled trial. Participants will be 
randomised to receive individual PM+, group PM+ or the control (no PM+), in a ratio 
of 1:1:1. 
 
The pilot trial is being conducted in Liverpool City Region. It utilises collaborative 
working between three universities (University of Liverpool, Liverpool John Moores 
University and Bangor University) and threefour NGOs offering advice and support 
to AS&Rs: PSS, and Asylum Link and , British Red Cross and Refugee Women 
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Trial participants will be asylum seekers and refugees. This includes those with 
pre-asylum status; those who have been offered either discretionary or indefinite 
leave to remain in the UK; those whose applications for leave to remain are 
pending or have been refused; those with humanitarian protection; those with 
refugee status; stateless people; and people on the vulnerable person resettlement 
programme.  
The other inclusion criteria are: 
 Aged ≥18 years (self-reported). 
 Score of ≥8 on either the depression or anxiety subscale of The Hospital 
Anxiety and Depression Scale (HADS)31, and score of ≥17 on the World 
Health Organisation Disability Assessment Schedule 2.0 (WHODAS)32. 
 Have conversational English, as self-assessed by the potential participant. 
 Registered with a general practitioner (GP) in Liverpool City Region. 
 Willing to provide relevant socioeconomic data. 
 Provided written informed consent. 
The exclusion criteria are:  
 New arrivals to the UK (less than 28 days), due to high likelihood of 
dispersal outside the region. 
 In reception centres, usually known as Initial Accommodation, and 
receiving temporary financial support under Section 98 of the Immigration 
and Asylum Act 1999 for less than 28 days, also due to high likelihood of 
dispersal outside the region. 
 Imminent risk of suicide: assessed by researchers using formal protocols 
with supervision and arbitration from qualified healthcare professionals. 
 Complex mental disorder (bipolar disorder/manic depression, or 
schizophrenia): Assessed by researcher on basis of: participant self-
reporting a diagnosis; and/or participant currently in receipt of 
antipsychotic medication, defined as medication listed in British National 
Formulary Chapter 2 section 2.3 (bipolar disorder and mania) and section 
2.6 (psychoses and schizophrenia). If required, further clinical assessment 
will occur using standard formal protocols. 
 Cognitive impairment (moderate/severe intellectual disability, any 
dementia). Assessed by researcher on basis of participant or carer self-
report. 
 Substance misuse: assessed by researcher on basis of participant response 
to the question: 'are you currently having problems with alcohol, cocaine, 
marijuana or any other drugs?' If response is yes or equivocal, then 
participant will be excluded. If required, further clinical assessment will 
occur using standard formal protocols. 
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Outcome measures 
Specific outcome measures, which are candidates for inclusion in any future 
definitive trial of PM+ for AS&Rs, will be tested as part of PROSPER Pilot. These are 
summarised in Table 1 below.  
 
Table 1: PROSPER Outcome Measures 
 
 HADS is a well-established 14-item scale consisting of 2 subscales: HADS-A 
(anxiety; 7 items; possible score range, 0-21) and HADS-D (depression; 7 
items; possible score range, 0-21). Higher scores indicate more anxiety 
and/or depression. HADS has been widely used across cultures; it is sensitive 
to change over time and has good internal consistency, reliability and 
validity38. 
 WHO-5 is validated in international studies for both clinical and 
psychometric properties and available in many languages. 
Objective 
 
Outcome Measures Timepoint(s) of 
evaluation 
Efficacy:   
Severity of combined anxiety 
and depressive symptoms 
Hospital Anxiety and 
Depression Scale (HADS)31 
Baseline, 13 week 
and 26 week follow 
up assessments 
Functional impairment WHO Disability Assessment 
Schedule (WHODAS)32 
Subjective wellbeing WHO-5 Wellbeing Index33  
Progress with problems for 





Post-traumatic Stress Disorder 
(PTSD)  
Post-traumatic Stress 
Disorder Checklist for 
DSM-5 (PCL-5)35 
Depressive Disorder 9-item Patient Health 
Questionnaire (PHQ-9)36 
Health Economics:   
Use of services and supports 
from NHS, social care and 
voluntary sectors 
Adapted Client Service 
Receipt Inventory (CSRI)37 
Baseline, 13 week 
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 WHODAS is applicable across all health states including mental disorders. It 
has good validity in terms of internal consistency, test-retest reliability, and 
agreement with other measures of disability across countries. 
 PSYCHLOPS has internal consistency, convergent validity with measures of 
emotional distress, and is sensitive to change.  It covers 3 domains: 
problems (2 questions), functioning (1 question), and well-being (1 
question). 
 PCL-5 has good psychometric properties for diagnostic accuracy and internal 
consistency. 
 PHQ-9 is based on DSM-IV depression diagnostic criteria. Total severity score 
ranges from 0 to 27, with 10 as conventional cut-off to diagnose depressive 
disorder. 
 The CSRI has been adapted for the PROSPER trial to include health, social 




Other elements of PROSPER Pilot will be assessed and used to inform the feasibility 
of conducting a full trial, as specified in Table 2: 
 
Table 2:  PROSPER feasibility measures 
 
Objective Outcome Measure Timepoint(s) of 
evaluation 
To assess the feasibility of the 
proposed procedures for 
recruiting distressed AS&Rs as 
study participants 
 











To assess the feasibility of 
retaining study participants 
through to trial completion 
Number of study 
participants in the trial 
(assessed in individual 
arms) 
26 weeks 
To assess the acceptability and 
utility of specified primary and 
secondary outcome measures 
 
Completion of study 
measures and estimation 
of between group 
differences 
 
Evaluation of outcome 
measures 
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The feasibility of progression to a definitive multi-centre randomised controlled 
trial will be informed by the extent to which the criteria below have been met 
using a go, amend, stop system, as specified in Table 3: 
 
Table 3: PROSPER Progression Criteria 
Progression 
Criteria 
Go Amend Stop 
Recruitment of 
trial participants 
≥70% of target  50-69% of target <50% of target 
Retention of trial 
participants 

















≥70% of measures 








If criteria meet ‘amend’ targets, reasons for this will be investigated with an aim 
to identify aspects amenable to change. If criteria meet ‘stop’ targets, reasons will 
be analysed and discussion within the project management group and with 
independent oversight committees. If it is determined that these rates cannot be 
improved then a full trial will not be recommended. 
 
Other progression criteria involving data from PROSPER Pilot that will be assessed 
by the research team are: 
 Recruitment of supervisors and lay therapists 
 Retention of lay therapists 
 Acceptability of outcome measures 
 Whether clinically important improvement in outcomes are plausible. 
Intervention  
The PM+ intervention consists of five weekly face-to-face sessions, delivered either 
one-to-one or in groups. The first session opens with psychoeducation, including 
information on common reactions to adversity, the rationale for PM+, goal setting, 
and brief motivational interviewing. Sessions one to four each introduce an 
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Problems (using problem solving techniques); (iii) Get Going, Keep Doing (applying 
behavioural activation techniques); and (iv) Strengthening Social Support. These 
strategies are applied by participants during the intervention session to problems 
they are facing. Each strategy is reviewed in subsequent sessions, with application 
of strategies between sessions encouraged to enhance learning through repetition. 
The final session involves a revision of learning, education on preventing relapse, 
and (for group PM+) ends with a culturally appropriate closing ceremony.  
 
To enhance accessibility for groups, the group PM+ intervention is structured 
around locally relevant and appropriate pictorial materials and adopts a narrative 
format to support engagement and individual disclosure of personal difficulties 
which can be more difficult in a group format. Specifically, a case example of a 
woman or a man (depending on the gender of group participants) experiencing 
common functioning and emotional problems is shared each week, with 
participants following their progress through PM+ Group. 
 
All PM+ sessions will take place at mutually convenient and safe locations, where 
support is available if required. Sessions will be delivered within organisations 
which have on-site staff with experience and training in managing emotional 
distress. No face-to-face sessions will take place in the home of either a 
participant or lay therapist. There will be no special criteria for discontinuing or 
modifying allocated interventions.  
Protocol adherence 
Consistent with an apprenticeship model39, protocol adherence is ensured through 
regular (at least fortnightly) supervision of the lay therapists provided by two 
Wellbeing Mentors. Involving all individual or group lay therapists in a group, 
supervision will last up to three hours and will entail reviewing the progress of 
intervention delivery, including case-management of participants and additional 
refresher training on intervention components. The group PM+ lay therapists will 
receive the same as individual PM+ lay therapists, in addition to refresher training 
on group facilitation skills, through role-play.  
 
The Wellbeing Mentors are in turn provided supervision by one of the Master 
Trainers, conducted at least monthly during the trial and lasting two hours. In 
addition, Wellbeing Mentors will have the day-to-day support of their line manager 
at PSS who also participated in the 5-day PM+ training with Master Trainers, and 
who participates in the monthly supervision sessions with the Master Trainer to 
ensure supervision consistency. 
 
Intervention fidelity will be monitored through independent observations of 15% of 
randomly selected sessions of each lay therapist against tailored checklists, 
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completed by lay therapists after each PM+ session and will capture information 
regarding timing, length and content of sessions. The logs will be passed to the 
Wellbeing Mentors at weekly supervision meetings. A small number of sessions may 
be audio- or video-recorded as an additional assessment of intervention fidelity. 
Feedback from intervention observations will be used in subsequent supervision 
sessions to improve adherence to intervention protocols. 
 
 
Intervention compliance by trial participants will be measured by assessing 
adherence to the PM+ protocol with regards to attendance at sessions.  
Control arm 
Participants randomised to the control arm will not be offered any PM+ but will be 
able to access all usual care and support offered by the participating NGOs. To 
control for the weekly contact that the active arms will receive, participants 
randomised to the control arm will be invited by the interviewing researcher 
to attend a local AS&R NGO of their choice. They will be put in contact with other 
AS&Rs from similar backgrounds and encouraged to meet together on a weekly 
basis for five weeks. 
 
Participant Identification  
Potential participants will be identified primarily through NGOs and primary care 
teams, all designated as Participant Information Agencies (PIAs).  PIAs will be 
provided with a short summary of the study including the main inclusion and 
exclusion criteria.  They will be asked to display posters and leaflets and discuss 
the study opportunistically with AS&Rs who access the services. All participant-
facing documentation will have the necessary approvals from a Research Ethics 
Committee.   
 
Potential participants will be made known to the research team via one of the 
following methods: 
 By them contacting the research team directly via telephone or email;  
 By agreeing to their details being given to the research team (via a 
participant recommendation form, completed by the PIA with the AS&R, and 
returned to the research team by the PIA); 
 By attending a researcher-attended drop-in session at collaborating NGOs on 
a specific date/time, advertised by posters/leaflets/verbally 
 
Following identification of a potential participant, a postdoctoral researcher based 
in the University of Liverpool, who is trained in the PROSPER trial techniques and 
in discussion about informed consent, will arrange a meeting to give more 
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Informed Consent  
The researcher will contact the potential participant to arrange an individual face-
to-face meeting. This meeting will be arranged at the convenience of the AS&R 
where possible and can be attended by an interpreter if required. The meeting will 
last between one and two hours. It will take place at a convenient location which 
could include one of the NGO centres, a community centre, a counselling centre, 
NHS premises and the University of Liverpool. 
 
Objectives, risks and inconveniences of the trial and the conditions under which it 
is to be conducted will be provided by the researcher. All potential participants 
will be given the opportunity to ask any questions that may arise, will have the 
opportunity to discuss the study with others and be given time to consider the 
information prior to agreeing to participate. It will be made clear to the 
participant that an eligibility assessment will be conducted once consent is given 
and that if the participant is found to be ineligible for any reason that they will be 
unable to participate. 
 
The potential participant will be asked to read and review the Participant 
Information Sheet (PISC), which is available in English and the study languages of 
Farsi, Urdu, and Arabic. Upon reviewing the document, the researcher will explain 
the research study to the potential participant. The PISC and the discussion with 
the participant will emphasise that participation in the trial is voluntary and that 
the participant may withdraw from the trial at any time and for any reason. 
Participants will also be asked for permission for the research team to share 
relevant data with people from the Universities taking part in the research or from 
regulatory authorities, where relevant. This trial does not involve collecting 
biological specimens for storage. The researcher is aware of the sensitive nature of 
the research topic and will minimise any distress caused to potential participants 
as a result of the discussions.  
 
If the asylum seeker or refugee decides that they would like to participate, he or 
she will then personally sign and date the informed consent document. The 
document will then be signed and dated by the person obtaining consent. A copy of 
the informed consent document will be given to the potential participant for their 
records. The original document will be maintained by the research team separate 
from any personal identifiable information collected for any participants. A further 
copy will be sent to the Liverpool Clinical Trial Centre (LCTC) via secure methods if 
the participant is eligible for full trial participation; this will be sent separately 
from any participant data subsequently collected. The PISC (which includes 
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If the potential participant requires more time to consider involvement in the trial 
a further meeting can be arranged at the discretion of the researcher. If the 
individual does not wish to take part, their reason for not providing consent will be 
recorded on the PROSPER Screening Log.  Once consent has been given the 
participant may, without being subject to any resulting detriment, withdraw from 
the trial at any time by revoking the informed consent.  
 
 
Eligibility and baseline assessments 
Once written informed consent has been obtained, the potential participant can be 
assessed for eligibility, as per the criteria detailed above. 
 
Eligibility assessment will follow a staged process. The researcher will review 
responses at the end of each stage, and if the potential participant is found to be 
ineligible they will be informed of this and there will be no requirement for 
completion of the next stage.  
 
Firstly, through discussion with the potential participant, the researcher will 
complete sociodemographic questions. The researcher will then assess the 
following exclusion criteria: complex mental disorder (bipolar disorder/manic 
depression, or schizophrenia); cognitive impairment (moderate/severe intellectual 
disability, any dementia); substance misuse; currently receiving a formal 
psychological therapy.  If the potential participant remains eligible, they will be 
asked to self-complete the HADS, WHODAS and PHQ-9 questionnaires within the 
Eligibility Questionnaire Booklet. These questionnaires are all available in English, 
Arabic, Farsi and Urdu. The researcher will review the completed PHQ-9 
questionnaire to assess whether the potential participant is at imminent risk of 
suicide. If there are any concerns regarding suicide risk, the researcher will follow 
the procedure outlined in the Suicidal Ideation Guidance Document.  
 
If the potential participant is eligible following this process, the researcher will 
conduct the baseline assessments outlined in the following section. This will allow 
consistency for outcome measurement completion, and also reduce the need for 
attendance at additional meetings. If the researcher has any concerns or 
uncertainties from the non-clinical eligibility assessment above, they will contact 
the Chief Investigator (CI) or nominated deputy to discuss the case. 
 
AS&Rs who are assessed as ineligible can be reconsidered for participation at a 
later date if circumstances change e.g. if they are able to register with a GP. If 
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Following the completion of the eligibility assessment, the researcher will ask the 
eligible participant to self-complete the Baseline Questionnaire Booklet, which 
incorporates the remaining baseline assessments: the WHO-5, PSYCHLOPS and PCL-
5 questionnaires. The CSRI Form, which has been adapted for PROSPER, will be 
completed by the researcher through discussion with the participant.  
 
For a potential participant who completes the eligibility assessment process and is 
deemed eligible to participate in PROSPER Pilot, but where there was concern or 
uncertainty that necessitated the researcher contacting the CI or nominated 
deputy, the CI or nominated deputy will review the information provided by the 
participant to verify eligibility for trial participation and complete the Eligibility 
and Baseline CRF before randomisation occurs. 
Randomisation  
Participants will be randomised using a secure web-based randomisation program. 
Randomisation lists will be generated in a 1:1:1 ratio, to individual PM+, group PM+ 
and control, using block randomisation with random variable block sizes.  
 
The randomisation list will be generated by a statistician independent to the 
PROSPER trial. Given the open nature of the trial, it will not be possible to blind 
researchers, trial participants, care providers, outcome assessors or data analysts 
to the intervention arm to which participants are assigned.  
 
The researcher will update the PROSPER Screening Log when a participant has 
been randomised.  The researcher will be responsible for notifying the participant 
of their allocation. In the event that a participant is randomised individual or 
group PM+, the researcher will inform the PSS Lead. Intervention delivery will be 
coordinated by PSS in collaboration with the participant and their lay therapist. 
The research team will notify the participant’s GP by letter of their enrolment into 
the trial and to what treatment arm they have been allocated.  
Assessments and Follow-up 
All assessments and follow up will be conducted in line with the Schedule of 
Assessments summarised in Table 4 
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Consent, Eligibility screening and confirmation  
Written and Informed 
Consent 
X    
Assess Eligibility X    
Confirm Eligibility X    
Randomisation  X   
Confirm Consent  X X X 
Data Collection 
HADS X  X X 
WHODAS X  X X 
PHQ-9 X  X X 
PSYCHLOPS X  X X 
PCL-5 X  X X 
WHO-5 X  X X 
CSRI X  X X 
Adverse Events 
Assessment of AEs X  X X 
 
In the case of premature discontinuation/withdrawal, there are no additional 
assessments for participants. 
 
All specified outcomes will be measured at 13 (± 2) and 26 (± 2) weeks post-
baseline. 13 weeks will be the primary end point: this is consistent with previous 
trials (Rahman et al, 2016). It allows time for intervention delivery and often may 
corresponds to the timings of Home Office decisions on leave to remain for asylum 
seekers.  
 
Follow Up Visit 1 – 13 week follow up 
This is expected to be a face-to-face appointment at 13 weeks ± 2 weeks from 
baseline, and include: 
 Verbal confirmation of continued consent; 
 The participant will complete the following questionnaires within the 
Follow Up Questionnaire Booklet: HADS, WHODAS, PHQ-9, WHO-5, 
PSYCHLOPS, PCL-5;  
 If suicidal ideation is disclosed or suspected, the researcher will follow 
the steps outlined in the Suicidal Ideation Guidance document; 
 Recording of any adverse event information; 
 Researcher-led completion of the adapted CSRI; 
 Completion of Follow Up CRF 
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This is expected to be a face-to-face appointment at 26 weeks ± 2 weeks from 
baseline, and to follow the same process as the follow up appointment at 13 
weeks. 
 
All follow up appointments will be coordinated and conducted by the trained 
researcher. They will conduct a preliminary review of the data collected to screen 
for missing data or any responses that may need further follow up or clinical 
discussion. Follow up appointments are expected to take around 1 hour which 
should allow for completion of all data collection and review of any adverse 
events. If a face-to-face appointment cannot be arranged during the follow up 
window then the visit can be conducted by telephone if possible. If the research 
team are unable to make arrangements to administer the assessments, the option 
of the participant self-completing the assessments and returning them by post will 
be explored. It is expected that participant responses will be completed during the 
appropriate visit window. 
The PROSPER Pilot study design is summarised in Figure 1. 





A detailed statistical analysis plan (SAP) will be developed prior to the first 
comparative monitoring report to be presented to the Independent Data and 
Safety Monitoring Committee (IDSMC). The main features of these planned 
statistical analyses, which refer specifically to the PROSPER pilot, are detailed 
below.  
 
The aim is to recruit 105 participants, 35 to each of three arms - individual PM+, 
group PM+ and control. Individual sessions will be offered as gender- and language-
specific, i.e. the lay therapist and the study participant will be the same gender 
and will be comfortable in a common language. At least four groups will be offered 
for the group intervention, each with up to 8 or 9 participants, each gender-
specific, i.e. participants will all be the same gender and at least one of the lay 
therapists will be of the same gender as the participants.  
 
The sample size needs to be sufficient to estimate retention levels in a definitive 
trial. With an expectation of 80% retention, samples of 35 participants for each of 
the individual, group and control arm will provide an accurate estimate of 
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Retention rates will be assessed in each arm separately, as there may be 
systematic differences between them; for example, those randomised to the 
control arm may be less likely to remain engaged than those randomised to the 
individual or group arms, while those randomised to the group arm may be 
demotivated if faced with a lengthy wait for their group to begin. 
 
No formal interim analysis is planned as this is a pilot study and there are no 
anticipated problems that are detrimental to the participant. There will be 
monitoring by the IDMSC, who will provide a recommendation to the Trial Steering 
Committee (TSC) on the continuation of the trial. 
 
Analysis will be by the intention-to-treat principle as far as is practically possible. 
All analyses will be descriptive, focussed on assessing the criteria for deciding 
whether to progress to a full trial. All estimates of proportions will be presented 
with 95% confidence intervals. Rates of recruitment and attrition will be presented 
both for lay therapists and trial participants, along with the proportion of PM+ 
interventions which are successfully delivered per protocol. The proportion of 
missing data in the proposed trial outcome measures will be assessed.  
 
Preliminary exploration of estimates of efficacy will involve a group-wise 
comparison of the primary outcome: severity of combined anxiety and depressive 
symptoms at 13 weeks post-baseline measured using the Hospital Anxiety and 
Depression Scale.  
 
Socio-demographic data, and use of services and supports will be captured by the 
adapted Client Service Receipt Inventory37. This data can be used for a wide range 
of applications, including estimating the costs of service receipt and societal costs. 
 
No formal testing of intervention effect will be carried out, but estimates of 
between group differences between the test groups and the control in outcome 
measures will be presented, with 95% confidence intervals, to assess whether a 
clinically important improvement in outcome would be plausible in a full trial. The 
effect of clustering by intervention provider on outcomes in the two PM+ groups 
will be investigated, to inform design of a full trial with a partially nested design. 
Process Evaluation and Feasibility Assessment 
Relevance and acceptability of proposed outcomes will be tested, with a view to 
their incorporation or refinement for a definitive trial. These will include:  
 Effectiveness of PM+, based on the primary outcome of combined HADS scores;  
 Cost-effectiveness of PM+ from an NHS perspective, based on the primary 
outcome of combined HADS scores40,41. 
 Cost benefit from a societal perspective, given that costs and potential benefits 
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 Impact on health inequalities using the NIHR CLAHRC NWC Health Inequalities 
Assessment Toolkit (www.hiat.org.uk): first, within AS&R communities in 
relation to age, gender, nationality, education, prior occupation and asylum 
status; and second, between AS&Rs and national populations, comparing 
mental health status (anxiety, depression PTSD and wellbeing) with UK 
population norms, with reference to published psychiatric morbidity data45.  
 
The feasibility of the 13- and 26-week time points will be assessed, with specific 
reference to rates of participant attrition. 
 
Researchers will undertake a systems-based process evaluation46, beginning three 
months into the PROSPER Pilot, to: understand service provider and participant 
experiences and perspectives on acceptability, efficiency, implementation and 
development of PM+; understand service-users’ perceptions and experiences of 
accessing and participating in PM+; explore how PM+ fits into existing health/social 
care systems; and understand change process dynamics including barriers and 
facilitators to implementing PM+. An ethnographic method will be adopted 
including observation of PM+ implementation alongside semi-structured interviews 
and focus group discussions with key stakeholder groups such as lay therapists, 
Wellbeing Mentors, PM+ participants, representatives from NGOs working with 
AS&R communities, health professionals and commissioners from Liverpool City 
Region. Heterogeneity within the population will be considered and whether the 
intervention’s feasibility and effectiveness may differ by demography or asylum 
status, and how this may influence the choice of target population for our 
proposed definitive trial.  
 
Analysis will be based on narrative synthesis, combining data tabulation and 
narrative techniques. This will involve iterative review and refinement in order to 
reach agreement on a set of general propositions in relation to the data.  The 
perspectives of Normalisation Process Theory47,48 will be used to assess the 
potential for implementing a full randomised controlled trial, focussing on the 
progression criteria set out above. 
 
Discontinuation and withdrawal 
In consenting to the trial, participants agree to all trial activities including 
administration of trial intervention and follow-up assessments / visits and data 
collection. Every effort will be made to facilitate the completion of these for every 
recruited participant. If it is not possible to complete these activities (or it is 
deemed inappropriate) the reasons why should be documented.  
 
Participants may discontinue the study intervention for reasons including, but not 
limited to: 
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 Researcher/Clinician/Lay therapist-led: 
- Any change in the participant’s condition that justifies the 
discontinuation of the intervention in the researcher/clinician/lay 
therapist’s opinion; 
- Reasons of non-adherence or non-compliance with study intervention 
or other trial procedures e.g. unable to complete course of PM+; 
- Participant meets an exclusion criterion (either newly developed or 
not previously recognised). 
 
Discontinuation from PM+ does not mean discontinuation of the study altogether, 
and the remaining study procedures i.e. 13- and 26-week follow up visits and data 
collection, and process evaluation, will be completed as indicated in the protocol 
(unless consent is specifically withdrawn). 
 
Participants are free to withdraw from follow up at any time without providing a 
reason, though a reason should be recorded if one is given. Those who wish to 
withdraw from further follow-up will have the data collected up to the point of 
that withdrawal included in the analyses. The participant will not contribute 
further data to the study and the LCTC will be informed, via email to the LCTC and 
via completion of a Withdrawal CRF to be returned to the LCTC within 24 hours.  
Death of a participant would be recorded on a Withdrawal CRF and a Death CRF. 
 
For participants moving from the area, every effort will be made for the 
participant to be followed-up and to complete their remaining study 
appointment(s) remotely.   
 
A participant will be considered lost to follow up if s/he fails to return for any 
scheduled visits and is not contactable by the site research team. If a participant 
fails to attend/facilitate a required study visit the following actions must be taken: 
 The researcher will attempt to contact the participant and reschedule the 
missed visit (be conscious of acceptable windows for collecting valid data) 
and advise the participant on the importance of maintaining the assigned 
visit schedule. 
 Before a participant is deemed to be lost to follow up, the research team 
will make reasonable effort to regain contact with the participant. 
 If the participant continues to be unreachable they should be considered 
withdrawn from the study with a primary reason of lost to follow up and 
this should be recorded on the Withdrawal CRF. 
Confidentiality and access to data 
Forms which contain participant identifiers will be stored separately from the case 
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Participants’ data will not be released outside of the study without the written 
permission of the participant, documented in the consent form. 
The University of Liverpool and Bangor University are registered as data controllers 
with the Information Commissioner’s Office. 
Safety and monitoring 
Safety assessments will be based on information disclosed by the participant 
throughout trial duration and by those who have knowledge of their welfare, 
including GPs, other health professional and NGO members. The Chief Investigator 
and other research staff are responsible for monitoring and reporting all adverse 
events.   
 
Ancillary and post-trial care will be the responsibility of the participant’s registered 
general practitioner.   
 
Data will be centrally monitored by the LCTC to promote data quality. Monitoring 
processes are documented in the ‘Trial Monitoring Plan’ and can be made available 
from the authors on request. If necessary, on-site monitoring visits can be 
triggered and will be carried out by either the LCTC or the sponsor representative. 
 
Safety information and data will be independently monitored by the IDSMC. The 
IDSMC is chaired by an independent senior clinical academic, and includes an 
independent methodological expert and an experienced service user. The IDSMC 
will report to the TSC, and hence to the NIHR Public Health Research Programme 
Board. The composition and terms of reference for both the IDSMC and the TSC are 
available from the authors on request.  
End of trial 
The end of the trial is defined to be the date on which data for all participants is 
locked and data entry privileges are withdrawn from the trial database. However, 




Using established procedures for knowledge exchange we will disseminate the 
findings of our research through: 
 Dedicated project web-page and social media sites; 
 Feedback to participants, both service users and providers; 
 Presentations to stakeholder groups including service users and providers, 
policy makers and commissioners, funders and benefactors; 
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 Presentations at clinical academic conferences; 
 Report for NIHR Public Health Research journal; 
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Discussion 
 
The PROSPER feasibility study and pilot trial will generate new knowledge of 
benefit to the health service and to society. This study will ascertain whether lay 
therapists based in NGOs can be trained to deliver PM+ with demonstrable 
evidence of capacity. It will provide early indications whether PM+ can lead to 
improvements in mental health and function for distressed AS&Rs in current UK 
settings. It will identify potential new pathways for access to care for these 
vulnerable groups, overcoming existing barriers such as accessibility of delivery 
locations and language barriers. 
 
There is currently a lack of evidence on feasibility of conducting research into 
psychosocial interventions in these circumstances, and this study will address this 
gap in the evidence-base. We anticipate that the study will provide clear evidence 
on the key parameters needed for a definitive randomised controlled trial in this 
field. Such a definitive trial has the potential to improve mental health, wellbeing 
and functional ability amongst AS&Rs, and to reduce health inequalities. This is 
likely to lead to more equitable and effective use of health care, with a shift from 
receiving emergency care to managed, proactive and preventive care. From a 
societal perspective, cost effectiveness and cost-benefit analyses following the 
definitive trial will indicate the extent to which the intervention confers both 
direct and indirect benefits. Public and patient involvement will ensure that the 
project delivers high quality, original evidence that has the potential to have a 
significant impact on the design of the definitive intervention and, subsequently, 
on policy and practice. 
 
From an international perspective, our findings will have relevance for other HICs 
hosting refugees, as well as for WHO recommendations on the use of PM+ with 
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AE Adverse Event 
AS&R Asylum Seeker and Refugee 
CI Chief Investigator 
CRF Case Report Form 
CSRI Client Service Receipt Inventory 
DSM-5 Diagnostic and Statistical Manual of Mental Disorders (5th edition) 
GP General Practitioner 
HADS Hospital Anxiety and Depression Scale 
HIC High Income Countries 
HRA Health Research Authority 
IAPT Increasing Access to Psychological Therapies 
IDSMC Independent Data and Safety Monitoring Committee 
LCTC Liverpool Clinical Trials Centre 
LMIC Low and Middle Income Countries 
NGO Non-Governmental Organisation 
NHS National Health Service 
NRES National Research Ethics Service 
NIHR CRN National Institute for Health Research Clinical Research Network 
PHQ-9 9-item Patient Health Questionnaire 
PI Principal Investigator 
PIA Participant Information Agency 
PM+ Problem Management Plus 
PMG Project Management Group 
PSS Person Shaped Support 
PSYCHLOPS Psychological Profiles Instrument 
PTSD Post-Traumatic Stress Disorder 
R&D Research & Development 
RCT Randomised Controlled Trial 
REC Research Ethics Committee 
RSI Reference Safety Information  
RSO Research Support Office 
SAE Serious Adverse Event 
SDV Source Data Verification 
SOP Standard Operating Procedure 
TSC Trial Steering Committee 
WHO World Health Organisation 
WHO-5 World Health Organisation Five Wellbeing Index 
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Figure 1: Schematic of Study Design 
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